Clarkston Discusses Impact of Novo-Catalent Deal on Big Pharma and CDMO Sector
November 13, 2024 | Clarkston partner and life sciences industry lead, Janel Firestein discusses how the Novo-Catalent deal highlights a shift in dynamics for Big Pharma and the CDMO industry. View a few of her quotes below and the full article here.
Novo-Catalent Deal Represents ‘Defining Moment’ for CDMO Sector
“During the pandemic, we talked a lot about supply chain resilience and shortages. This deal is reinforcing the need for companies to look at supply chain resilience across their portfolio and look at the potential risks that come into play, such as manufacturing capacity within a CDMO that gets acquired or a facility being sold off,” Firestein said.
[She explained to BioSpace that, prior to COVID-19, the trend had been to divest manufacturing capabilities and instead outsource to contract manufacturers, but post-pandemic, this movement is now reversing, with more pharma companies working to secure access to manufacturing capacity through acquisitions or building facilities. In turn, this means that companies working with CDMOs are operating in a riskier environment.]